Europe Emerging Infectious Disease Diagnostics Market: Analysis and Forecast, 2023-2033
This report will be delivered in 1-5 working days.
Introduction to Europe Emerging Infectious Disease Diagnostics Market
The Europe emerging infectious disease diagnostics market was valued at $4.70 billion in 2023 and is expected to reach $7.85 billion by 2033, growing at a CAGR of 5.28% between 2023 and 2033. The market for diagnosing emerging infectious diseases is experiencing growth due to several key factors. These factors encompass the economic impact of infectious diseases, financial support from governments through funding and partnerships, rising demand for point-of-care and syndromic testing, and advancements in molecular diagnostics technology.
Market Introduction
The European emerging infectious disease diagnostics market is characterized by a diverse array of methods and techniques aimed at identifying and detecting infectious agents swiftly and accurately. This sector plays a crucial role in the timely diagnosis of diseases, facilitating appropriate treatment decisions and public health responses. Within Europe, microbiological culture remains a fundamental method, involving the cultivation of patient specimens on specialized growth media to isolate and identify specific pathogens. This allows for the precise determination of the causative organism and an assessment of its susceptibility to antimicrobial agents. In addition, molecular diagnostics, a rapidly evolving field, is gaining prominence. Techniques like polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) are extensively employed, offering highly sensitive and specific pathogen identification, even at low concentrations. With ongoing technological advancements and a growing emphasis on public health, the European market for emerging infectious disease diagnostics is poised for continuous development and innovation.
Market Segmentation:
Segmentation 1: by Application
Product/Innovation Strategy: The Europe emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The Europe emerging infectious disease diagnostics market is fragmented, with several established as well as emerging players. Key players in the Europe emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
Introduction to Europe Emerging Infectious Disease Diagnostics Market
The Europe emerging infectious disease diagnostics market was valued at $4.70 billion in 2023 and is expected to reach $7.85 billion by 2033, growing at a CAGR of 5.28% between 2023 and 2033. The market for diagnosing emerging infectious diseases is experiencing growth due to several key factors. These factors encompass the economic impact of infectious diseases, financial support from governments through funding and partnerships, rising demand for point-of-care and syndromic testing, and advancements in molecular diagnostics technology.
Market Introduction
The European emerging infectious disease diagnostics market is characterized by a diverse array of methods and techniques aimed at identifying and detecting infectious agents swiftly and accurately. This sector plays a crucial role in the timely diagnosis of diseases, facilitating appropriate treatment decisions and public health responses. Within Europe, microbiological culture remains a fundamental method, involving the cultivation of patient specimens on specialized growth media to isolate and identify specific pathogens. This allows for the precise determination of the causative organism and an assessment of its susceptibility to antimicrobial agents. In addition, molecular diagnostics, a rapidly evolving field, is gaining prominence. Techniques like polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) are extensively employed, offering highly sensitive and specific pathogen identification, even at low concentrations. With ongoing technological advancements and a growing emphasis on public health, the European market for emerging infectious disease diagnostics is poised for continuous development and innovation.
Market Segmentation:
Segmentation 1: by Application
- Laboratory Testing
- Point-of-Care Testing
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Next-Generation Sequencing (NGS)
- Immunodiagnostics
- Other Technologies
- Bacterial
- Viral
- Fungal
- Other Infections
- Respiratory Infections
- Sexually Transmitted Infections (STIs)
- Gastrointestinal Infections
- Other Infections
- Hospitals and Clinics
- Diagnostic Laboratories
- Other End Users
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
Product/Innovation Strategy: The Europe emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The Europe emerging infectious disease diagnostics market is fragmented, with several established as well as emerging players. Key players in the Europe emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
- bioMйrieux S.A
- DiaSorin S.p.A
- F. Hoffmann-La Roche Ltd
- QIAGEN N.V.
- Tecan Trading AG
- Siemens Healthineers AG
Executive Summary
Scope of the Study
Research Methodology
1 MARKETS
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Key Findings
1.2 Industry Outlook
1.2.1 Market Overview
1.2.1.1 Timeline of Emerging Technologies for Infectious Disease Diagnostics
1.2.1.2 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
1.2.1.3 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
1.2.1.4 Current Market Landscape of Emerging Infectious Disease Diagnostics
1.2.1.5 Future Potential
1.2.1.5.1 CRISPR
1.2.1.5.2 NGS
1.2.1.5.3 INAAT
1.2.1.5.4 Digital PCR (dPCR)
1.2.2 Patent Analysis
1.2.2.1 By Year
1.2.2.2 By Country/Organization
1.2.3 Pipeline Analysis
1.2.4 Impact of COVID-19 on Infectious Disease Diagnostics
1.2.4.1 Post-COVID-19 Scenario: A Paradigm Shift to Home-Based Testing
1.2.5 Supply Chain Analysis
1.3 Market Dynamics
1.3.1 Impact Analysis
1.3.2 Drivers
1.3.2.1 Economic Burden of Infectious Diseases
1.3.2.2 Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases Through Funding and Collaboration
1.3.2.3 Increasing Demand for Point-of-Care (POC) and Syndromic Testing
1.3.2.4 Technological Advancements in Molecular Diagnostics
1.3.2.4.1 Isothermal Nucleic Acid Amplification Techniques (INAATs)
1.3.2.4.2 Digital PCR
1.3.2.4.3 CRISPR Technologies
1.3.3 Restraints
1.3.3.1 Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases
1.3.3.2 Erratic Trend in Infectious Disease Epidemic Outbreaks Globally
1.3.3.3 Lack of an Established Framework for NGS-based Tests for Infectious Diseases
1.3.4 Opportunities
1.3.4.1 Potential of Molecular Diagnostic Tests in Low-Resource Settings
1.3.4.2 Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance
2 EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET (BY REGION)
2.1 Europe Emerging Infectious Disease Diagnostics Market
2.1.1 Regulatory Framework
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Emerging Infectious Disease Diagnostics Market (by Application)
2.1.3.2 Europe Emerging Infectious Disease Diagnostics Market (by Technology)
2.1.3.3 Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection)
2.1.3.4 Europe Emerging Infectious Disease Diagnostics Market (by Disease Type)
2.1.3.5 Europe Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.1 Germany
2.1.3.5.1.1 Market Dynamics
2.1.3.5.1.2 Market Size and Forecast
2.1.3.5.1.2.1 Germany Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.2 U.K.
2.1.3.5.2.1 Market Dynamics
2.1.3.5.2.2 Market Size and Forecast
2.1.3.5.2.2.1 U.K. Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.3 France
2.1.3.5.3.1 Market Dynamics
2.1.3.5.3.2 Market Size and Forecast
2.1.3.5.3.2.1 France Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.4 Italy
2.1.3.5.4.1 Market Dynamics
2.1.3.5.4.2 Market Size and Forecast
2.1.3.5.4.2.1 Italy Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.5 Spain
2.1.3.5.5.1 Market Dynamics
2.1.3.5.5.2 Market Size and Forecast
2.1.3.5.5.2.1 Spain Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.6 Rest-of-Europe
2.1.3.5.6.1 Market Dynamics
2.1.3.5.6.2 Market Size and Forecast
2.1.3.5.6.2.1 Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User)
3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
3.1 Competitive Landscape
3.1.1 Overview
3.1.2 Corporate Strategies
3.1.2.1 Mergers and Acquisitions
3.1.2.2 Synergistic Activities
3.1.2.3 Business Expansions and Funding
3.1.3 Business Strategies
3.1.3.1 Product Launches/Upgradations/Approvals
3.2 Market Share Analysis
3.3 Emerging Infectious Disease Diagnostics Ecosystem Active Players
3.4 Company Profiles
3.4.1 bioMйrieux S.A.
3.4.1.1 Company Overview
3.4.1.2 Role of bioMйrieux S.A. in the Emerging Infectious Disease Diagnostics Market
3.4.1.3 Financials
3.4.1.1 Recent Developments
3.4.1.2 Analyst Perspective
3.4.2 DiaSorin S.p.A.
3.4.2.1 Company Overview
3.4.2.2 Role of DiaSorin S.p.A. in the Emerging Infectious Disease Diagnostics Market
3.4.2.3 Financials
3.4.2.4 Recent Developments
3.4.2.5 Analyst Perspective
3.4.3 F. Hoffmann-La Roche Ltd
3.4.3.1 Company Overview
3.4.3.2 Role of F. Hoffmann-La Roche Ltd in the Emerging Infectious Disease Diagnostics Market
3.4.3.3 Financials
3.4.3.4 Recent Developments
3.4.3.5 Analyst Perspective
3.4.4 QIAGEN N.V.
3.4.4.1 Company Overview
3.4.4.2 Role of QIAGEN N.V. in the Emerging Infectious Disease Diagnostics Market
3.4.4.3 Financials
3.4.4.4 Recent Developments
3.4.4.5 Analyst Perspective
3.4.5 Tecan Trading AG
3.4.5.1 Company Overview
3.4.5.2 Role of Tecan Trading AG in the Emerging Infectious Disease Diagnostics Market
3.4.5.3 Financials
3.4.5.4 Recent Developments
3.4.5.5 Analyst Perspective
3.4.6 Siemens Healthineers AG
3.4.6.1 Company Overview
3.4.6.2 Role of Siemens Healthineers AG in the Emerging Infectious Disease Diagnostics Market
3.4.6.3 Financials
3.4.6.4 Recent Developments
3.4.6.5 Analyst Perspective
3.5 Company Snapshots
3.5.1 En Carta Diagnostics
3.5.1.1 Company Overview
3.5.1.2 Role of En Carta Diagnostics in the Emerging Infectious Disease Diagnostics Market
List of Figures
Figure 1: Europe Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 2: Europe Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 3: Europe Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
Figure 4: Europe Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
Figure 5: Share of Key Developments, January 2019-June 2023
Figure 6: Market Share Analysis for Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 7: Key Insights Validated from Primary Interviews
Figure 8: Emerging Infectious Disease Diagnostics Market Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Top-Down Approach (Segment-Wise Analysis)
Figure 12: Timeline of Emerging Technologies for Infectious Disease Diagnostics
Figure 13: Advantages of Emerging Infectious Disease Diagnostic Technologies
Figure 14: Limitations of Emerging Infectious Disease Diagnostic Technologies
Figure 15: Key Settings of POC Testing Deployment
Figure 16: Key Challenges Associated with Point-of-Care Testing
Figure 17: Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 18: Future Potential of NGS in Infectious Disease Diagnostics
Figure 19: Number of Molecular Diagnostics Patents for Infectious Diseases (by Year)
Figure 20: Number of Molecular Diagnostic Patents for Infectious Diseases (by Country/Organization)
Figure 21: Key Benefits of Home-Based Testing
Figure 22: Typical Supply Chain for a Diagnostic Test
Figure 23: Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 24: Fiscal Response to the COVID-19 Pandemic (% of GDP)
Figure 25: Advantages of Point-of-Care Tests in Molecular Diagnostics
Figure 26: Key Clinical Areas Demanding Commercial Availability of Syndromic Tests
Figure 27: Advantages of INAAT over PCR
Figure 28: Number of LAMP Publications on Public Databases, 2016-2022
Figure 29: Number of INAAT Publications on Public Databases, 2016-2022
Figure 30: Advantages of Digital PCR over Quantitative Real-Time PCR
Figure 31: Number of “Digital PCR” Publications on Public Databases, 2016-2022
Figure 32: Europe Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 33: Europe Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
Figure 34: Europe Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 35: Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Billion, 2022-2033
Figure 36: Europe Emerging Infectious Disease Diagnostics Market (by Disease Type), $Billion, 2022-2033
Figure 37: Europe Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 38: Europe Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
Figure 39: Germany Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 40: Germany Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 41: U.K. Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 42: U.K. Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 43: France Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 44: France Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 45: Italy Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 46: Italy Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 47: Spain Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 48: Spain Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 49: Rest-of-Europe Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 50: Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 51: Share of Key Developments, January 2019-June 2023
Figure 52: Number of Mergers and Acquisitions (by Company), January 2019-June 2023
Figure 53: Share of Synergistic Activities (by Company), January 2019-June 2023
Figure 54: Number of Business Expansions and Funding Activities (by Company), January 2019-June 2023
Figure 55: Number of Product Launches/Upgradations/Approvals (by Company), January 2019-June 2023
Figure 56: Market Share Analysis for Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 57: Emerging Infectious Disease Diagnostics Market, Total Number of Companies Profiled
Figure 58: bioMйrieux S.A.: Product Portfolio
Figure 59: bioMйrieux S.A.: Overall Financials, $Million, 2020-2022
Figure 60: bioMйrieux S.A.: Revenue (by Segment), $Million, 2020-2022
Figure 61: bioMйrieux S.A.: Revenue (by Region), $Million, 2020-2022
Figure 62: bioMйrieux S.A.: R&D Expenditure, $Million, 2020-2022
Figure 63: DiaSorin S.p.A.: Product Portfolio
Figure 64: DiaSorin S.p.A.: Overall Financials, $Million, 2021-2022
Figure 65: DiaSorin S.p.A.: Revenue (by Region), $Million, 2021-2022
Figure 66: DiaSorin S.p.A.: R&D Expenditure, $Million, 2021-2022
Figure 67: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 68: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 69: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 70: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 71: QIAGEN N.V.: Product Portfolio
Figure 72: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 73: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 74: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 75: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 76: Tecan Trading AG: Product Portfolio
Figure 77: Tecan Trading AG: Overall Financials, $Million, 2020-2022
Figure 78: Tecan Trading AG: Revenue (by Segment), $Million, 2020-2022
Figure 79: Tecan Trading AG: Revenue (by Region), $Million, 2020-2022
Figure 80: Tecan Trading AG: R&D Expenditure, $Million, 2020-2022
Figure 81: Siemens Healthineers AG: Product Portfolio
Figure 82: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 83: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
Figure 84: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 85: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
Figure 86: En Carta Diagnostics: Overall Product Portfolio
Scope of the Study
Research Methodology
1 MARKETS
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Key Findings
1.2 Industry Outlook
1.2.1 Market Overview
1.2.1.1 Timeline of Emerging Technologies for Infectious Disease Diagnostics
1.2.1.2 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
1.2.1.3 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
1.2.1.4 Current Market Landscape of Emerging Infectious Disease Diagnostics
1.2.1.5 Future Potential
1.2.1.5.1 CRISPR
1.2.1.5.2 NGS
1.2.1.5.3 INAAT
1.2.1.5.4 Digital PCR (dPCR)
1.2.2 Patent Analysis
1.2.2.1 By Year
1.2.2.2 By Country/Organization
1.2.3 Pipeline Analysis
1.2.4 Impact of COVID-19 on Infectious Disease Diagnostics
1.2.4.1 Post-COVID-19 Scenario: A Paradigm Shift to Home-Based Testing
1.2.5 Supply Chain Analysis
1.3 Market Dynamics
1.3.1 Impact Analysis
1.3.2 Drivers
1.3.2.1 Economic Burden of Infectious Diseases
1.3.2.2 Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases Through Funding and Collaboration
1.3.2.3 Increasing Demand for Point-of-Care (POC) and Syndromic Testing
1.3.2.4 Technological Advancements in Molecular Diagnostics
1.3.2.4.1 Isothermal Nucleic Acid Amplification Techniques (INAATs)
1.3.2.4.2 Digital PCR
1.3.2.4.3 CRISPR Technologies
1.3.3 Restraints
1.3.3.1 Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases
1.3.3.2 Erratic Trend in Infectious Disease Epidemic Outbreaks Globally
1.3.3.3 Lack of an Established Framework for NGS-based Tests for Infectious Diseases
1.3.4 Opportunities
1.3.4.1 Potential of Molecular Diagnostic Tests in Low-Resource Settings
1.3.4.2 Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance
2 EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET (BY REGION)
2.1 Europe Emerging Infectious Disease Diagnostics Market
2.1.1 Regulatory Framework
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Emerging Infectious Disease Diagnostics Market (by Application)
2.1.3.2 Europe Emerging Infectious Disease Diagnostics Market (by Technology)
2.1.3.3 Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection)
2.1.3.4 Europe Emerging Infectious Disease Diagnostics Market (by Disease Type)
2.1.3.5 Europe Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.1 Germany
2.1.3.5.1.1 Market Dynamics
2.1.3.5.1.2 Market Size and Forecast
2.1.3.5.1.2.1 Germany Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.2 U.K.
2.1.3.5.2.1 Market Dynamics
2.1.3.5.2.2 Market Size and Forecast
2.1.3.5.2.2.1 U.K. Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.3 France
2.1.3.5.3.1 Market Dynamics
2.1.3.5.3.2 Market Size and Forecast
2.1.3.5.3.2.1 France Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.4 Italy
2.1.3.5.4.1 Market Dynamics
2.1.3.5.4.2 Market Size and Forecast
2.1.3.5.4.2.1 Italy Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.5 Spain
2.1.3.5.5.1 Market Dynamics
2.1.3.5.5.2 Market Size and Forecast
2.1.3.5.5.2.1 Spain Emerging Infectious Disease Diagnostics Market (by End User)
2.1.3.5.6 Rest-of-Europe
2.1.3.5.6.1 Market Dynamics
2.1.3.5.6.2 Market Size and Forecast
2.1.3.5.6.2.1 Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User)
3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
3.1 Competitive Landscape
3.1.1 Overview
3.1.2 Corporate Strategies
3.1.2.1 Mergers and Acquisitions
3.1.2.2 Synergistic Activities
3.1.2.3 Business Expansions and Funding
3.1.3 Business Strategies
3.1.3.1 Product Launches/Upgradations/Approvals
3.2 Market Share Analysis
3.3 Emerging Infectious Disease Diagnostics Ecosystem Active Players
3.4 Company Profiles
3.4.1 bioMйrieux S.A.
3.4.1.1 Company Overview
3.4.1.2 Role of bioMйrieux S.A. in the Emerging Infectious Disease Diagnostics Market
3.4.1.3 Financials
3.4.1.1 Recent Developments
3.4.1.2 Analyst Perspective
3.4.2 DiaSorin S.p.A.
3.4.2.1 Company Overview
3.4.2.2 Role of DiaSorin S.p.A. in the Emerging Infectious Disease Diagnostics Market
3.4.2.3 Financials
3.4.2.4 Recent Developments
3.4.2.5 Analyst Perspective
3.4.3 F. Hoffmann-La Roche Ltd
3.4.3.1 Company Overview
3.4.3.2 Role of F. Hoffmann-La Roche Ltd in the Emerging Infectious Disease Diagnostics Market
3.4.3.3 Financials
3.4.3.4 Recent Developments
3.4.3.5 Analyst Perspective
3.4.4 QIAGEN N.V.
3.4.4.1 Company Overview
3.4.4.2 Role of QIAGEN N.V. in the Emerging Infectious Disease Diagnostics Market
3.4.4.3 Financials
3.4.4.4 Recent Developments
3.4.4.5 Analyst Perspective
3.4.5 Tecan Trading AG
3.4.5.1 Company Overview
3.4.5.2 Role of Tecan Trading AG in the Emerging Infectious Disease Diagnostics Market
3.4.5.3 Financials
3.4.5.4 Recent Developments
3.4.5.5 Analyst Perspective
3.4.6 Siemens Healthineers AG
3.4.6.1 Company Overview
3.4.6.2 Role of Siemens Healthineers AG in the Emerging Infectious Disease Diagnostics Market
3.4.6.3 Financials
3.4.6.4 Recent Developments
3.4.6.5 Analyst Perspective
3.5 Company Snapshots
3.5.1 En Carta Diagnostics
3.5.1.1 Company Overview
3.5.1.2 Role of En Carta Diagnostics in the Emerging Infectious Disease Diagnostics Market
List of Figures
Figure 1: Europe Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 2: Europe Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 3: Europe Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
Figure 4: Europe Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
Figure 5: Share of Key Developments, January 2019-June 2023
Figure 6: Market Share Analysis for Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 7: Key Insights Validated from Primary Interviews
Figure 8: Emerging Infectious Disease Diagnostics Market Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Top-Down Approach (Segment-Wise Analysis)
Figure 12: Timeline of Emerging Technologies for Infectious Disease Diagnostics
Figure 13: Advantages of Emerging Infectious Disease Diagnostic Technologies
Figure 14: Limitations of Emerging Infectious Disease Diagnostic Technologies
Figure 15: Key Settings of POC Testing Deployment
Figure 16: Key Challenges Associated with Point-of-Care Testing
Figure 17: Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 18: Future Potential of NGS in Infectious Disease Diagnostics
Figure 19: Number of Molecular Diagnostics Patents for Infectious Diseases (by Year)
Figure 20: Number of Molecular Diagnostic Patents for Infectious Diseases (by Country/Organization)
Figure 21: Key Benefits of Home-Based Testing
Figure 22: Typical Supply Chain for a Diagnostic Test
Figure 23: Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 24: Fiscal Response to the COVID-19 Pandemic (% of GDP)
Figure 25: Advantages of Point-of-Care Tests in Molecular Diagnostics
Figure 26: Key Clinical Areas Demanding Commercial Availability of Syndromic Tests
Figure 27: Advantages of INAAT over PCR
Figure 28: Number of LAMP Publications on Public Databases, 2016-2022
Figure 29: Number of INAAT Publications on Public Databases, 2016-2022
Figure 30: Advantages of Digital PCR over Quantitative Real-Time PCR
Figure 31: Number of “Digital PCR” Publications on Public Databases, 2016-2022
Figure 32: Europe Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 33: Europe Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
Figure 34: Europe Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 35: Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Billion, 2022-2033
Figure 36: Europe Emerging Infectious Disease Diagnostics Market (by Disease Type), $Billion, 2022-2033
Figure 37: Europe Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 38: Europe Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
Figure 39: Germany Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 40: Germany Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 41: U.K. Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 42: U.K. Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 43: France Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 44: France Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 45: Italy Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 46: Italy Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 47: Spain Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 48: Spain Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 49: Rest-of-Europe Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 50: Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 51: Share of Key Developments, January 2019-June 2023
Figure 52: Number of Mergers and Acquisitions (by Company), January 2019-June 2023
Figure 53: Share of Synergistic Activities (by Company), January 2019-June 2023
Figure 54: Number of Business Expansions and Funding Activities (by Company), January 2019-June 2023
Figure 55: Number of Product Launches/Upgradations/Approvals (by Company), January 2019-June 2023
Figure 56: Market Share Analysis for Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 57: Emerging Infectious Disease Diagnostics Market, Total Number of Companies Profiled
Figure 58: bioMйrieux S.A.: Product Portfolio
Figure 59: bioMйrieux S.A.: Overall Financials, $Million, 2020-2022
Figure 60: bioMйrieux S.A.: Revenue (by Segment), $Million, 2020-2022
Figure 61: bioMйrieux S.A.: Revenue (by Region), $Million, 2020-2022
Figure 62: bioMйrieux S.A.: R&D Expenditure, $Million, 2020-2022
Figure 63: DiaSorin S.p.A.: Product Portfolio
Figure 64: DiaSorin S.p.A.: Overall Financials, $Million, 2021-2022
Figure 65: DiaSorin S.p.A.: Revenue (by Region), $Million, 2021-2022
Figure 66: DiaSorin S.p.A.: R&D Expenditure, $Million, 2021-2022
Figure 67: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 68: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 69: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 70: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 71: QIAGEN N.V.: Product Portfolio
Figure 72: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 73: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 74: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 75: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 76: Tecan Trading AG: Product Portfolio
Figure 77: Tecan Trading AG: Overall Financials, $Million, 2020-2022
Figure 78: Tecan Trading AG: Revenue (by Segment), $Million, 2020-2022
Figure 79: Tecan Trading AG: Revenue (by Region), $Million, 2020-2022
Figure 80: Tecan Trading AG: R&D Expenditure, $Million, 2020-2022
Figure 81: Siemens Healthineers AG: Product Portfolio
Figure 82: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 83: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
Figure 84: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 85: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
Figure 86: En Carta Diagnostics: Overall Product Portfolio
LIST OF TABLES
Table 1: Some of the Key Developments By Companies Leveraging Emerging Technologies in Infectious Disease Diagnostics
Table 2: Key Product Offerings by Players in the Emerging Infectious Disease Diagnostics Market
Table 3: Key Questions Answered in the Report
Table 4: Some of the RT-LAMP Assays Developed during COVID-19
Table 5: Molecular Diagnostic Products for Infectious Diseases Under Development
Table 6: At-Home COVID-19 Kits Approved for Commercial Use by ICMR
Table 7: Examples of International Research Consortiums for Managing Response to Infectious Diseases
Table 8: List of Infectious Disease Outbreaks (by Region and Year)
Table 9: Europe Emerging Infectious Disease Diagnostics Market, Impact Analysis
Table 10: Emerging Infectious Disease Diagnostics Market, Key Active Players
Table 1: Some of the Key Developments By Companies Leveraging Emerging Technologies in Infectious Disease Diagnostics
Table 2: Key Product Offerings by Players in the Emerging Infectious Disease Diagnostics Market
Table 3: Key Questions Answered in the Report
Table 4: Some of the RT-LAMP Assays Developed during COVID-19
Table 5: Molecular Diagnostic Products for Infectious Diseases Under Development
Table 6: At-Home COVID-19 Kits Approved for Commercial Use by ICMR
Table 7: Examples of International Research Consortiums for Managing Response to Infectious Diseases
Table 8: List of Infectious Disease Outbreaks (by Region and Year)
Table 9: Europe Emerging Infectious Disease Diagnostics Market, Impact Analysis
Table 10: Emerging Infectious Disease Diagnostics Market, Key Active Players
